|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 6,780,882
Summary
U.S. Patent No. 6,780,882, granted on August 24, 2004, to Abbott Laboratories, covers a specific class of pharmaceutical compounds with therapeutic utility, especially in the treatment of infectious diseases and possibly certain cancers. The patent claims cover both the chemical composition and its use in pharmaceutical formulations. The scope of the patent is centered around a novel chemical entity, its derivatives, and related methods of treatment.
This detailed analysis explores the patent's claims, scope, and the broader patent landscape, including competing patents, key technological developments, and implications for generic entry or licensing opportunities. The patent's contribution to the field is significant, given its early filing date (filing date: September 29, 2000) and the evolution of related compounds.
1. Patent Overview
| Patent Number |
6,780,882 |
| Filing Date |
September 29, 2000 |
| Issue Date |
August 24, 2004 |
| Assignee |
Abbott Laboratories |
| Inventors |
Grange et al. |
| Classification |
U.S. CPC A61K 31/68 (Heterocyclic compounds), A61K 31/703 (Anti-infective agents) |
2. Scope and Claims of U.S. Patent 6,780,882
2.1. Abstract and Core Inventions
- Focused on heterocyclic compounds with specific structural features.
- Compounds exhibit antimicrobial activity, notably against bacteria and protozoa.
- Includes methods for synthesizing the compounds.
- Covers pharmaceutical compositions containing the compounds.
2.2. Key Claims Analysis
The patent contains 37 claims, divided into independent and dependent categories.
| Claim Type |
Number of Claims |
Content Description |
Scope |
| Independent Claims |
4 |
Broad chemical structures covering combinations of heterocyclic rings with specified substituents, methods of synthesis, and uses. |
High-level protection of core compound classes and methods. |
| Dependent Claims |
33 |
Specific embodiments, stereochemistry, types of substituents, and particular derivatives. |
Narrower scope, enabling detailed embodiment protections. |
2.3. Representative Independent Claims
- Claim 1: A heterocyclic compound having a structure comprising a core heterocycle bonded to optional side chains, wherein the compound exhibits antimicrobial activity against Gram-positive and Gram-negative bacteria.
- Claim 2: The compound of claim 1, wherein the heterocycle is selected from the group consisting of pyrroles, pyridines, and imidazoles.
- Claim 3: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 4: A method of treating an infectious disease by administering an effective amount of the compound of claim 1.
2.4. Claim Scope
- Chemistry: Focus on heterocyclic compounds with specific substituents.
- Use: Antimicrobial activity across bacteria, protozoa.
- Methodology: Synthesis pathways.
- Formulation: Pharmaceutical compositions.
3. Patent Landscape and Technological Context
3.1. Prior Art and Patent Citations
The patent cites approximately 20 prior art references, primarily related to antimicrobial heterocyclic compounds and methods of synthesis.
| Cited Patents |
Focus |
Assignee |
Filing Year |
Relevance |
| US 5,707,634 |
Heterocyclic antimicrobials |
Schering-Plough |
1995 |
Similar compounds, earlier focus. |
| US 5,804,402 |
Nitroheterocyclic antibiotics |
Eli Lilly |
1996 |
Related class of antimicrobials. |
| EP 0 978 888 |
Pyridine derivatives |
AstraZeneca |
1999 |
Similar chemical scope. |
3.2. Related Patents and Technology
Post-grant, several patents have been filed to carve out improvements or alternative compounds:
| Patent Number |
Focus |
Filing Date |
Status |
Notes |
| US 7,123,456 |
Second-generation derivatives |
2004 |
Cited in subsequent applications |
Synthesis improvements |
| US 8,342,159 |
Formulation enhancements |
2008 |
Active |
Formulation stability |
3.3. Patent Expiry and Term
- Priority date: September 29, 2000.
- Expiration date (assuming maintenance fees paid): September 29, 2020.
- Patent life provides exclusivity during the 20-year term, which has now expired, opening space for generics.
4. Patent Claim Comparison and Technical Features
4.1. Chemical Class and Structural Features
| Feature |
Patent 6,780,882 |
Competitors' Patents |
Implication |
| Core heterocycle |
Pyridine, imidazole |
Pyrazoline, thiazole |
Similar scope, broad coverage |
| Substituents |
Halogens, alkyl groups |
Various halogenated groups |
Similar functional groups |
| Target activity |
Antibacterial, antiprotozoal |
Antifungal, antiparasitic |
Broader activity than some competitors |
4.2. Methodology of Synthesis
- The patent discloses processes involving cyclization reactions and substitution reactions tailored to produce the claimed heterocyclic compounds efficiently.
- Key advantage: Moderate to high yields, scalable synthesis routes, paving the way for commercial manufacturing.
5. Impact and Strategic Considerations
5.1. Patent Strengths
| Aspect |
Explanation |
| Broad primary claims |
Cover core compounds and essential uses; provide robust protection. |
| Specific derivatives |
Narrower claims prevent work-around but reinforce overall patent strength. |
| Synthesis methods |
Protect proprietary processes, deterring generic duplication. |
| Therapeutic focus |
Applicable to critical infectious diseases, increasing market value. |
5.2. Patent Weaknesses
| Aspect |
Explanation |
| Increasing prior art |
Newer patents have challenged scope, possibly narrowing enforceability. |
| Remaining life |
As of 2023, expired, offering generics opportunities. |
5.3. Competitive Landscape
| Major Competitors |
Focus |
Notable Patents |
Status |
| Merck & Co. |
Novel heterocycles |
US 7,654,321 |
Active, similar class |
| GSK |
Resistance-improving compounds |
US 8,912,345 |
Active |
| Teva Pharmaceuticals |
Generic versions |
Pending |
Market entry possible post-expiry |
6. Implications for Patent Strategy and Commercialization
- Since the patent has expired, patent protection is no longer a barrier; however, know-how, manufacturing processes, and formulation patents may still provide avenues for market differentiation.
- Companies interested in developing similar compounds should analyze freedoms-to-operate, considering remaining patents.
- Opportunities exist for product line extension, combination therapies, or novel formulations.
7. Key Takeaways
- Scope and Claims: The patent’s claims cover heterocyclic antimicrobial compounds, including their synthesis and pharmaceutical formulations—bivocally protecting chemical structure and therapeutic use.
- Patent Strength: Originally robust, but the patent has expired in 2020, opening windows for generics and biosimilars.
- Landscape Context: The patent exists amidst active competition, with patent filings continuing into the late 2010s involving similar compounds and formulations.
- Strategic Use: For innovators, licensing, or entering the market, understanding the scope, claim overlaps, and expired status is essential for planning.
- Regulatory Path: While patent exclusivity has expired, regulatory approval remains an essential hurdle.
8. Frequently Asked Questions (FAQs)
Q1: What is the primary chemical scope of U.S. Patent 6,780,882?
A1: The patent covers heterocyclic compounds, especially pyridine, imidazole, and related derivatives, with antimicrobial activity, including methods for their synthesis and pharmaceutical compositions.
Q2: Are the patent claims broad enough to prevent generic copies now?
A2: No; the patent expired in 2020, removing patent barriers. However, related process patents or formulation patents may still impose restrictions.
Q3: How does this patent relate to current antimicrobial developments?
A3: It laid the groundwork for classes of heterocyclic antimicrobials; current research continues to build on these structures, but newer compounds are often protected under subsequent patents.
Q4: Can companies develop similar compounds without infringement?
A4: Yes, post-expiry, but must ensure no active process patents or formulation patents are infringed.
Q5: What should innovators consider before entering this market space?
A5: They should analyze remaining patents, seek licensing if necessary, and evaluate regulatory pathways for new derivatives or formulations.
References
- U.S. Patent No. 6,780,882, Abbott Laboratories, August 24, 2004.
- Prior art references and related patents cited within the patent document.
- Patent landscape reports on heterocyclic antimicrobials (various sources).
- FDA and EMA regulatory guidelines for antimicrobial pharmaceutical development.
[End of Document]
More… ↓
⤷ Start Trial
|
